Peptide Knowledge Base · Metabolic
Tesofensine: what it is, what the evidence says, and its real status
A non-peptide triple-reuptake inhibitor studied as an appetite suppressant, not US-approved, with cardiovascular and psychiatric cautions.
Short version: not a peptide, a centrally-acting appetite suppressant that is not US-approved and carries real cardiovascular and psychiatric cautions. A caution page, not an offer.
Can you actually get it?
Plain-English verdict: Education only.
Regulatory status: Not US-approved · Education only.
Not offered, caution and education only. Tesofensine is a non-peptide triple-reuptake inhibitor, not US-approved, with cardiovascular and psychiatric risk signals. We do not provide it.
How does Tesofensine work?
A non-peptide inhibitor of noradrenaline, dopamine, and serotonin reuptake that suppresses appetite centrally.
What it does — and what it does not do
What it does: Showed appetite suppression and weight loss in earlier human trials.
What it does not do: It is not US-approved, not a peptide, and not safe to obtain off-market given cardiovascular and psychiatric risk.
How honest is the evidence?
Evidence grade C — some human trial data; not approved; safety signals. Read our grading methodology for what each grade means.
What we still don't know: Long-term cardiovascular and neuropsychiatric safety are the unresolved questions that gate approval.
WADA status: Not prohibited.
How it is taken
Not offered; education only.
Who should not take it
Cardiovascular disease, hypertension, psychiatric history; not US-approved.
Sources
Tesofensine obesity trial literature (not US-approved)
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.